Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
Fersiynau electronig
Dogfennau
- 2017 Cost effectiveness analysis
Llawysgrif awdur wedi’i dderbyn, 957 KB, dogfen-PDF
Dangosydd eitem ddigidol (DOI)
(ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained.
Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.
Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.
| Iaith wreiddiol | Saesneg |
|---|---|
| Tudalennau (o-i) | 1729-1739 |
| Cyfnodolyn | Rheumatology |
| Cyfrol | 56 |
| Rhif y cyfnodolyn | 10 |
| Dyddiad ar-lein cynnar | 14 Gorff 2017 |
| Dynodwyr Gwrthrych Digidol (DOIs) | |
| Statws | Cyhoeddwyd - 1 Hyd 2017 |
Cyfanswm lawlrlwytho
Nid oes data ar gael